Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 2 | 0 | 2 |
| 2017 | 33 | 6 | 39 |
| 2018 | 27 | 3 | 30 |
| 2019 | 19 | 4 | 23 |
| 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study. J Clin Rheumatol. 2022 03 01; 28(2):e348-e352.
-
Healthcare system conversion to a biosimilar: Trials and tribulations. Am J Health Syst Pharm. 2021 Nov 23; 78(23):2159-2163.
-
A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia. Respir Med. 2021 09; 186:106541.
-
Evidence-based public policy making for medicines across countries: findings and implications for the future. J Comp Eff Res. 2021 08; 10(12):1019-1052.
-
National trends in prescription drug expenditures and projections for 2021. Am J Health Syst Pharm. 2021 07 09; 78(14):1294-1308.
-
Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey. Int J Clin Pract. 2021 Sep; 75(9):e14341.
-
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021 08; 17(8):e1235-e1245.
-
Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform. Molecules. 2021 Mar 29; 26(7).
-
ß-glucans: wide-spectrum immune-balancing food-supplement-based enteric (ß-WIFE) vaccine adjuvant approach to COVID-19. Hum Vaccin Immunother. 2021 08 03; 17(8):2808-2813.
-
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells. 2021 02 04; 10(2).